Merck & Co., Inc. logo
Merck & Co., Inc. (MRK)
Compare

Merck & Co., Inc. (MRK) EV/Sales Ratio: 5.22x

popular:market cap|pe ratio|revenue|price history|total return

Is Merck & Co., Inc.’s EV/Sales ratio high or low?

Merck & Co., Inc.'s EV/Sales ratio of 5.22x is in line with its 5-year average of 4.77x, around the middle of its 5-year range (3.31x–6.10x).

As of Thursday, June 11, 2026. 20.45% above its 12-month average of 4.33x.

EV/EBITDA|P/S Ratio|Revenue|All Metrics

MRK EV/Sales Ratio Chart

MRK EV/Sales Ratio
5.22x+45.40% 1Y
Zoom

MRK Average EV/Sales Ratio Chart

MRK Current vs Average EV/Sales Ratio Chart

MRK EV/Sales Ratio Metrics

EV/SALES RATIO

5.22x

EV/SALES RATIO AVG TTM

4.33x

EV/SALES RATIO AVG 3Y

4.75x

EV/SALES RATIO AVG 5Y

4.77x

EV/SALES RATIO AVG 10Y

4.73x

EV/SALES RATIO AVG 15Y

4.28x

EV/SALES RATIO AVG 20Y

4.03x

CURRENT VS TTM AVG

+20.45%

CURRENT VS 3Y AVG

+9.91%

CURRENT VS 5Y AVG

+9.53%

CURRENT VS 10Y AVG

+10.32%

CURRENT VS 15Y AVG

+21.88%

CURRENT VS 20Y AVG

+29.48%

MRK Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
Merck & Co., Inc. (MRK)$298.23B5.22x4.33x4.75x4.77x
UnitedHealth Group Incorporated (UNH)$369.16B0.93x0.80x1.18x1.36x
AbbVie Inc. (ABBV)$399.86B7.40x7.46x6.80x6.33x
Amgen Inc. (AMGN)$188.37B6.15x6.19x6.53x6.38x
Thermo Fisher Scientific Inc. (TMO)$176.21B4.80x5.13x5.38x5.61x
Gilead Sciences, Inc. (GILD)$156.35B5.61x6.02x4.98x4.64x
Abbott Laboratories (ABT)$155.75B4.07x4.94x5.00x4.98x
Pfizer Inc. (PFE)$149.61B3.37x3.30x3.43x3.63x
Intuitive Surgical, Inc. (ISRG)$144.79B13.82x18.43x19.52x18.69x
CVS Health Corporation (CVS)$126.70B0.48x0.44x0.43x0.51x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

Merck & Co., Inc. EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Merck & Co., Inc. EV/Sales Ratio FAQ

What is the EV/Sales ratio for Merck & Co., Inc. (MRK)?
The EV/Sales ratio for MRK stock is 5.22x.
Is Merck & Co., Inc.'s EV/Sales ratio high or low?
Merck & Co., Inc.'s EV/Sales ratio of 5.22x is in line with its 5-year average of 4.77x, around the middle of its 5-year range (3.31x–6.10x).
What is the TTM average EV/Sales ratio for Merck & Co., Inc. (MRK)?
The TTM average EV/Sales ratio for MRK stock is 4.33x.
What is the 3Y average EV/Sales ratio for Merck & Co., Inc. (MRK)?
The 3Y average EV/Sales ratio for MRK stock is 4.75x.
What is the 5Y average EV/Sales ratio for Merck & Co., Inc. (MRK)?
The 5Y average EV/Sales ratio for MRK stock is 4.77x.
What is the 10Y average EV/Sales ratio for Merck & Co., Inc. (MRK)?
The 10Y average EV/Sales ratio for MRK stock is 4.73x.
What is the 15Y average EV/Sales ratio for Merck & Co., Inc. (MRK)?
The 15Y average EV/Sales ratio for MRK stock is 4.28x.
What is the 20Y average EV/Sales ratio for Merck & Co., Inc. (MRK)?
The 20Y average EV/Sales ratio for MRK stock is 4.03x.

Merck & Co., Inc. EV/Sales Ratio History

DATEEV/SALES RATIO
2026-06-115.22x
2026-06-105.16x
2026-06-095.17x
2026-06-085.17x
2026-06-055.22x
2026-06-045.20x
2026-06-034.99x
2026-06-025.03x
2026-06-015.01x
2026-05-295.14x
2026-05-285.19x
2026-05-275.20x
2026-05-265.18x
2026-05-225.28x
2026-05-215.03x
2026-05-204.93x
2026-05-194.97x
2026-05-184.91x
2026-05-154.87x
2026-05-144.94x
2026-05-134.94x
2026-05-124.90x
2026-05-114.86x
2026-05-084.87x
2026-05-074.90x
2026-05-064.95x
2026-05-054.93x
2026-05-044.93x
2026-05-014.85x
2026-04-304.74x
2026-04-294.81x
2026-04-284.77x
2026-04-274.78x
2026-04-244.84x
2026-04-234.95x
2026-04-224.88x
2026-04-214.87x
2026-04-205.04x
2026-04-175.12x
2026-04-164.98x
2026-04-155.07x
2026-04-145.15x
2026-04-135.16x
2026-04-105.21x
2026-04-095.26x
2026-04-085.27x
2026-04-075.12x
2026-04-065.19x
2026-04-025.19x
2026-04-015.18x
2026-03-315.16x
2026-03-305.08x
2026-03-275.14x
2026-03-265.11x
2026-03-255.13x
2026-03-245.01x
2026-03-234.99x
2026-03-204.93x
2026-03-194.93x
2026-03-184.94x
2026-03-174.99x
2026-03-164.98x
2026-03-134.98x
2026-03-125.00x
2026-03-115.01x
2026-03-105.04x
2026-03-095.04x
2026-03-064.99x
2026-03-055.00x
2026-03-045.16x
2026-03-035.15x
2026-03-025.21x
2026-02-275.30x
2026-02-265.13x
2026-02-255.25x
2026-02-245.30x
2026-02-235.18x
2026-02-205.12x
2026-02-195.10x
2026-02-185.09x
2026-02-175.09x
2026-02-135.08x
2026-02-125.00x
2026-02-115.00x
2026-02-104.92x
2026-02-094.94x
2026-02-065.10x
2026-02-055.02x
2026-02-044.96x
2026-02-034.87x
2026-02-024.77x
2026-01-304.65x
2026-01-294.58x
2026-01-284.52x
2026-01-274.56x
2026-01-264.54x
2026-01-234.57x
2026-01-224.61x
2026-01-214.68x
2026-01-204.62x
2026-01-164.59x
2026-01-154.68x
2026-01-144.68x
2026-01-134.57x
2026-01-124.61x
2026-01-094.66x
2026-01-084.68x
2026-01-074.59x
2026-01-064.60x
2026-01-054.54x
2026-01-024.50x
2025-12-314.46x
2025-12-304.49x
2025-12-294.51x
2025-12-264.51x
2025-12-244.50x
2025-12-234.45x
2025-12-224.43x
2025-12-194.29x
2025-12-184.28x
2025-12-174.22x
2025-12-164.18x
2025-12-154.26x
2025-12-124.26x
2025-12-114.21x
2025-12-104.16x
2025-12-094.13x
2025-12-084.21x
2025-12-054.24x
2025-12-044.29x
2025-12-034.34x
2025-12-024.29x
2025-12-014.32x
2025-11-284.44x
2025-11-264.43x
2025-11-254.47x
2025-11-244.27x
2025-11-214.16x
2025-11-204.06x
2025-11-194.06x
2025-11-184.11x
2025-11-173.97x
2025-11-143.98x
2025-11-133.98x
2025-11-123.92x
2025-11-113.90x
2025-11-103.74x
2025-11-073.72x
2025-11-063.70x
2025-11-053.64x
2025-11-043.74x
2025-11-033.68x
2025-10-313.82x
2025-10-303.83x
2025-10-293.85x
2025-10-283.86x
2025-10-273.90x
2025-10-243.88x
2025-10-233.87x
2025-10-223.89x
2025-10-213.89x
2025-10-203.84x
2025-10-173.78x
2025-10-163.74x
2025-10-153.75x
2025-10-143.77x
2025-10-133.81x
2025-10-103.82x
2025-10-093.88x
2025-10-083.84x
2025-10-073.89x
2025-10-063.93x
2025-10-033.95x
2025-10-023.96x
2025-10-013.99x
2025-09-303.74x
2025-09-293.53x
2025-09-263.53x
2025-09-253.49x
2025-09-243.57x
2025-09-233.58x
2025-09-223.60x
2025-09-193.65x
2025-09-183.65x
2025-09-173.63x
2025-09-163.63x
2025-09-153.63x
2025-09-123.70x
2025-09-113.79x
2025-09-103.75x
2025-09-093.77x
2025-09-083.75x
2025-09-053.77x
2025-09-043.75x
2025-09-033.75x
2025-09-023.80x
2025-08-293.75x
2025-08-283.71x
2025-08-273.75x
2025-08-263.78x
2025-08-253.80x
2025-08-223.88x
2025-08-213.83x
2025-08-203.77x
2025-08-193.78x
2025-08-183.75x
2025-08-153.75x
2025-08-143.69x
2025-08-133.69x
2025-08-123.60x
2025-08-113.59x
2025-08-083.61x
2025-08-073.60x
2025-08-063.56x
2025-08-053.62x
2025-08-043.57x
2025-08-013.54x
2025-07-313.50x
2025-07-303.64x
2025-07-293.68x
2025-07-283.73x
2025-07-253.76x
2025-07-243.74x
2025-07-233.73x
2025-07-223.64x
2025-07-213.55x
2025-07-183.57x
2025-07-173.63x
2025-07-163.67x
2025-07-153.63x
2025-07-143.72x
2025-07-113.71x
2025-07-103.73x
2025-07-093.72x
2025-07-083.63x
2025-07-073.61x
2025-07-033.61x
2025-07-023.67x
2025-07-013.64x
2025-06-303.54x
2025-06-273.54x
2025-06-263.53x
2025-06-253.56x
2025-06-243.59x
2025-06-233.58x
2025-06-203.54x
2025-06-183.54x
2025-06-173.50x
2025-06-163.61x
2025-06-133.64x
2025-06-123.64x
2025-06-113.59x
2025-06-103.63x
2025-06-093.55x
2025-06-063.53x
2025-06-053.48x
2025-06-043.50x
2025-06-033.46x
2025-06-023.42x
2025-05-303.45x

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

Related Metrics

EV/EBITDAP/S RatioRevenueAll Metrics

About Merck & Co., Inc.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

Rahway, NJ
73,000 employees
www.merck.com
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Robert Davis
View full financials